Statewide Practice Enrolling Patients in Global, Late-Phase Clinical Trial
FORT MYERS, Fla., Jan. 22, 2026 /PRNewswire/ — Florida Cancer Specialists & Research Institute, LLC (FCS) is among the first oncology providers in Florida selected to enroll patients in a phase 3 clinical study of pasritamig, a new cancer therapy called a bispecific T‑cell engager, being developed by Johnson & Johnson for prostate cancer that has spread beyond the prostate and no longer responds to hormone therapy.Â
“This trial represents an exciting step forward in next-generation immunotherapy research for prostate cancer,” said Bradley Monk, MD, FCS medical director of late-phase clinical research, who leads initiatives across the statewide practice to monitor and evaluate the effectiveness of new drugs and therapies that are transforming cancer treatment worldwide.
Prostate cancer is the most commonly diagnosed malignancy worldwide and the sixth leading cause of cancer-related death in men. When confined to the prostate, the disease is considered localized and potentially curable. If the disease has spread outside the prostate, many cancers become resistant to available therapies.
FCS is among a select group of 172 locations globally participating in the trial that will evaluate the overall survival of patients given pasritamig in combination with best supportive care (BSC) as compared to placebo with BSC. Dr. Monk noted that this is FCS’ first enrollment to a late phase bispecific T-cell engager clinical trial. FCS offers step-up dosing and maintenance therapy with FDA-approved bispecific drugs to treat recurring and resistant blood cancers and small cell lung cancer.
“Treatment-resistant cancers pose a major challenge in medicine,” said Elizabeth Guancial, MD, FCS medical oncologist and hematologist who is serving as principal investigator. “I’m proud that FCS is helping lead this research—giving patients new hope and opportunities to participate in cutting-edge care, especially since the early phase data to support it was generated in our very own DDU. We believe this example of seamless drug development directly benefits our patients by providing faster access to next wave therapies.”Â
Pasritamig brings a patient’s T‑cells directly to prostate cancer cells by binding both the cancer cell protein KLK2 and the T‑cell receptor CD3, allowing the T‑cells to attack and kill the cancer. To learn more about the new phase 3 trial: https://clinicaltrials.gov/study/NCT07164443
FCS provides ongoing access to more than 180 clinical trials within 29 FCS clinics statewide and early-phase Drug Development Units (DDUs) located in Sarasota and Central Florida. In recent years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with FCS participation.
 For a complete list of FCS clinical trials: https://www.clinicaltrialnavigator.com/
About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program.
FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. In fact, before receiving FDA approval, the majority of new cancer drugs in the U.S. were first made available to patients through participation in clinical trials at FCS.
Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/florida-cancer-specialists–research-institute-among-first-in-florida-to-trial-next-generation-immunotherapy-for-castration-resistant-prostate-cancer-302668212.html
SOURCE Florida Cancer Specialists & Research Institute
